As for SARS-CoV2, this study in @cell_res found that CQ inhibited viral spread in a concentration-dependent fashion nature.com/articles/s4142… /5
Comparing HCQ and CQ against SARS-CoV2 in vitro, HCQ is clearly more potent. That's good news because it's also better tolerated clinically. academic.oup.com/cid/advance-ar… /6
What about clinical data? Early days, but this paper says CQ improved multiple outcomes in a study of >100 patients in China. (N.B. not much detail on methodology, and the result are from news briefing ...) jstage.jst.go.jp/article/bst/14… /7
Small, open-label study awaiting peer review. But it sure looks like HCQ (600 mg /day) hastens viral cure, maybe with a synergistic effect of azithromycin. /8
While that's encouraging, here's a thoughtful commentary in @ViralRes reminding us that chloroquine failed to do much for influenza and ebolavirus, and it actually worsened matters in a primate model of chikungunya. sciencedirect.com/science/articl… /9
What to do with all this? Not sure, but HCQ is pretty well tolerated. I'd give it a shot in confirmed COVID-19, maybe with azithromycin, until we have firmer data to guide us one way or the other.
Just my $0.02. Also, tweets are not medical advice.
Yes, the AstraZeneca vaccine-thrombosis association is causal.
The temporal relationship is strong, it’s not seen with mRNA vaccines, and there’s a plausible mechanism analogous to heparin-induced thrombocytopenia (HIT)
This report of a physician who died after receiving COVID vaccine offers a useful lesson in the importance of thinking more critically about does and what does not constitute a drug reaction.
/1 usatoday.com/story/news/hea…
Briefly, the MD noticed petechiae (tiny areas of bleeding into the skin, as seen in image) 3 days after vaccination. He was diagnosed with ITP (immune thrombocytopenic purpura).
People with ITP have profoundly low platelets and can bleed spontaneously as a result.
/2
The temptation to blame the vaccine is understandable: we’re hypervigilant about the safety of new drugs (especially high-profile ones employing a novel technology), and the timing seems like a slam dunk.
This thread of drug-specific tips has generated a series of podcasts with @JAMA_current's Ed Livingston (@ehlJAMA). I'll append them here as they are released.
I'd like to share some reflections on the death of a patient. I’ve thought about her a lot.
She gave me explicit consent to tweet the details of her case, about four hours before she died. Her hope was that someone might benefit from her experience.
/1
She came to hospital as octogenarians often do: with generalized weakness, falls, poor oral intake, fever, hypotension.
Her WBC was 17,000. Blood cultures grew E. coli.
Sepsis. Fixable enough.
/2
But she also complained of pain in her groin and thigh. It was new, progressive and debilitating.
Even moving around in her hospital bed was agonizing.
/3